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ABSTRACT 
 
OBJECTIVES 
We identified factors associated with thromboembolic and bleeding events in 
two contemporary cohorts of anticoagulated patients with atrial fibrillation 
(AF), treated with either vitamin K antagonists (VKA) or non-VKA oral 
anticoagulants (NOAC). 
 
DESIGN 
Prospective, multicentre observational study 
 
SETTING 
461 centres in 7 European countries 
 
PARTICIPANTS 
5310 patients receiving a VKA (PREFER in AF, derivation cohort) and 3156 
patients receiving a NOAC (PREFER in AF Prolongation, validation cohort) for 
stroke prevention in AF 
 
OUTCOME MEASURES 
Risk factors for thromboembolic events (ischemic stroke, systemic embolism) 
and major bleeding (gastrointestinal bleeding, intracerebral hemorrhage and 
other life-threatening bleeding) 
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RESULTS  
The mean age of patients enrolled in the PREFER in AF registry was 72±10 
years, 40% were female, and the mean CHA2DS2-VASc Score was 3.5±1.7. 
The incidence of thromboembolic and major bleeding events was 2.34% (95% 
CI 1.93-2.74) and 2.84% (95% CI 2.41-3.33) after 1 year of follow-up, 
respectively. 
Abnormal liver function, prior stroke or transient ischemic attack (TIA), labile 
international normalised ratio (INR), concomitant therapy with antiplatelet- or 
non-steroidal anti-inflammatory drugs (NSAIDs), heart failure, and older age 
(≥75 years) were independently associated with both thromboembolic and 
major bleeding events.  
With the exception of unstable INR values, these risk factors were validated in 
patients treated with NOACs (PREFER in AF Prolongation Study, 72±9 years, 
40% female, CHA2DS2-VASc 3.3±1.6). For each single point decrease on a 
modifiable bleeding risk scale we observed a 30% lower risk for major 
bleeding events (OR 0.70,95%CI 0.64-0.76, p<0.01) and a 28% lower rate of 
thromboembolic events (OR 0.72,95%CI 0.66-0.82, p<0.01). 
 
CONCLUSION 
Attending to modifiable risk factors is an important treatment target in 
anticoagulated AF patients to reduce thromboembolic and bleeding events. 
Initiation of anticoagulation in those at risk of stroke should not be prevented 
by elevated bleeding risk scores. 
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STRENGTHS AND LIMITATIONS OF THIS STUDY 
 
• We analysed a large and contemporary cohort of anticoagulated 
patients with atrial fibrillation (AF) enrolled across seven European 
countries  
• Our findings were validated in a second, independent cohort of AF 
patients receiving a NOAC for stroke prevention 
• These datasets were analysed in a retrospective fashion, thus our 
findings have to regarded as hypothesis generating. 
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INTRODUCTION 
Atrial fibrillation (AF) is a major risk factor for disabling stroke. Oral 
anticoagulation reduces the risk of stroke in patients with AF by almost two-
thirds, and is therefore recommended for most patients with AF. 1 2  
However, even on oral anticoagulation, stroke or systemic embolism occurs in 
1-4% of anticoagulated AF patients 3-7, and approximately 2% experience a 
major bleed per year. 8 Reducing this burden of residual adverse events is 
desirable to improve outcomes. 
To date, conditions predisposing to thromboembolic 3 9-18 and bleeding events 
4 18-22 in anticoagulated AF patients have not been fully investigated. Their 
identification could help to improve outcomes in anticoagulated patients with 
AF. We therefore sought to identify factors associated with thromboembolic 
events and major bleeding in AF patients treated with either vitamin K 
antagonists (VKA) or non-VKA oral anticoagulants (NOAC).  
 
METHODS 
 
Study Population 
We analysed outcomes in anticoagulated patients enrolled into the PREFER 
in AF (PREvention oF thromboembolic events – European Registry in Atrial 
Fibrillation) registry. 21  Baseline data were obtained from consecutive AF 
patients in seven European countries (Austria, France, Germany, Italy, Spain, 
Switzerland, and the UK) between January 2012 and January 2013. Patients 
were included if they were at least 18 years of age and had a history of AF 
documented by electrocardiography or by an implanted cardiac device within 
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the preceding 12 months. 21 
In order to reduce potential sources of bias and to achieve a cohort 
representative of the ´real world´, no explicit exclusion criteria were defined. 
Investigators were encouraged to enroll patients consecutively to reduce 
selection bias. 21 Patients receiving anticoagulation were included in the 
present analysis when information on outcome events was available during 
one year of follow-up. 
We validated our findings in the independent PREFER in AF Prolongation 
cohort which contained 3156 AF patients treated with a NOAC, who were 
enrolled between June 2014 and May 2015.  
 
Ethics Approval 
The study was carried out with the approval of the responsible ethics 
committees in the respective countries and in accordance with national law 
and the Helsinki Declaration of 1975 (in its current revised form). A list of the 
involved ethics committees is available in the Supplementary Appendix. All 
participants gave written informed consent.   
 
Outcome Definitions 
The combined ischemic endpoint consisted of ischemic stroke and systemic 
embolic events (SEE), including transient ischemic attack (TIA), arterial 
embolism, venous thromboembolism or pulmonary thromboembolism. 
The combined major bleeding endpoint included gastrointestinal bleeding 
requiring therapy, intracerebral hemorrhage and other life-threatening 
   7 
bleeding (resulting in substantial compromise requiring treatment). Outcomes 
were reported and adjudicated by the respective investigators at each site. 
 
Statistical Methods 
Discrete characteristics are expressed as frequency counts and percentages. 
Continuous characteristics are expressed as means and standard deviations 
or medians, where appropriate. Patients with missing data for outcome events 
or variables of interest were not included in the analysis. 
Multivariable logistic regression with a step-wise inclusion of covariates was 
used to identify predictors for thromboembolic events and major bleeding, 
including components of the validated HAS-BLED and CHA2DS2-VASc risk 
stratification scheme and other variables available in the registry. For the best 
performing clusters of thromboembolic events and major bleeding risk factors, 
optimal integer coefficients were estimated using combinatorial testing of all 
integer weights via a logistic regression stepwise selection model.  Cross 
validation was performed using bootstrapping (1000x random splitting of the 
cohort in 2 parts of identical in size). Predictors and integer coefficients in the 
first cohort were validated in the second cohort (which was not used for 
coefficient fitting). The most frequent predictors and for those the most 
frequent integer coefficients were presented as optimal integer coefficients. 
The average over 1000 runs is presented as bootstrapping AUC together with 
variability estimation. Sensitivity analysis was performed by testing integer 
versus continuous coefficients, alternative age cut-offs, adequate rate control, 
rhythm control, presence of sinus rhythm, use of rhythm control therapy, 
presence of chronic kidney disease and different blood pressure cut-offs.  
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The ROC contrast test was used to compare the predictive performance of 
the identified clusters of risk factors and established risk stratification 
schemes. 23-26 
The clusters of risk factors were independently validated in the PREFER in AF 
Prolongation Study, enrolling 3156 anticoagulated AF patients between June 
2014 and May 2015. Patients enrolled into both studies (PREFER in AF and 
PREFER in AF Prolongation) were excluded from the validation cohort. Labile 
international normalized ration (INR) was defined as unstable INR values 
<60% time in therapeutic range, as adjudicated and reported by the 
respective investigators at each site. 
SAS V. 9.4 was used for all statistical analysis.  
 
Patient Involvement 
Patients were not involved in planning, design and conduct of the PREFER in 
AF study. Results were disseminated through press releases by the funding 
body and the primary results of the PREFER in AF study are available 
through open access publication (DOI 10.1093/europace/eut263). 21 
 
 
 
 
RESULTS 
 
Patient characteristics 
The PREFER in AF registry enrolled 7243 patients in 461 European centres.  
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The clinical characteristics of the anticoagulated primary analysis population 
with available one-year follow-up (5310 patients) are reported in Table 1. All 
patients received oral anticoagulation, of whom 7.4% were treated with a non-
vitamin K antagonist oral anticoagulant (NOAC, dabigatran 64%, rivaroxaban 
34%, apixaban 2%). 
At one year follow-up, there were 124 thromboembolic events, with a 
corresponding annual rate of 2.34% (95% confidence interval, CI, 1.93-2.74) 
(Table 2). 
In total, 151 (2.84%, 95% CI 2.41-3.33) major bleeding events occurred in 145 
patients. Of these, 74 (1.39%, 95% CI 1.10-1.75) were gastrointestinal 
bleedings, 15 (0.28%, 95% CI 0.16-0.47) were intracerebral hemorrhages, 
and 68 (1.28%, 95% CI 1.00-1.62) were other life-threatening or major 
bleedings requiring therapy (6 patients experienced more than one bleeding 
episode). 
 
Best-performing cluster of risk factors for thromboembolic events 
Upon multivariable analysis a best-performing cluster of risk factors for 
thromboembolic events was identified. In descending order of relative risk, the 
inputs were abnormal liver function, prior stroke or transient ischemic attack 
(TIA), labile international normalised ratio (INR), concomitant therapy with 
antiplatelet- or non-steroidal anti-inflammatory drugs (NSAIDs), heart failure, 
and age ≥75 years (Table 3, Figure 1).  
Ninety-five percent of patients with a labile INR received a VKA during the 
entire follow-up period, thus, the confounding effect of patients switched to a 
NOAC was insignificant.   
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Adequacy of rate control, the presence of sinus rhythm on follow-up, use of 
antiarrhythmic drugs, chronic kidney disease and alternative age cut-offs did 
not improve the score. Uncontrolled hypertension levels were low (only 3.3% 
of patients >160 mmHg at 1 year), diminishing a statistical impact upon 
multivariable modeling.  
The C-index with respect to the combined endpoint of thromboembolic events 
was 0.7402 (95% CI 0.6868-0.7935, p<0.01 vs. HAS-BLED) (Supplementary 
Table 1). 
Sensitivity analysis for a combined ischemic endpoint excluding TIA, as well 
as for TIA only, show numerically consistent results (Supplementary Table 2 
and 3).  
 
Best-performing cluster of major bleeding risk factors 
The best performing cluster of major bleeding risk factors included modifiable 
inputs of the HAS-BLED score (except for hypertension, due to low exposure 
to elevated blood pressure levels), a modified age cut-off and vascular 
disease (Table 4, Figure 2). The C-index for major bleeding was 0.6982 (95% 
CI 0.6529-0.7469, p<0.01 vs. HAS-BLED) (Supplementary Table 1). 
For each single point decrease in this cluster of mostly modifiable bleeding 
risk factors we observed a 30% lower relative risk for major bleeding events 
(OR 0.70, 95% CI 0.64-0.76, p<0.01). When applied to evaluate the risk for 
thromboembolic events, there was a 28% lower event rate per point decrease 
on this adjusted modifiable bleeding risk scale (OR 0.72, 95%CI 0.66 -0.82, 
p<0.01). 
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Based on this observation, for each single point decrease on this best-
performing scale of modifiable bleeding risk factors, we estimate a number 
needed to treat (NNT) of 111 to prevent one major bleeding event (0.9% 
absolute risk reduction) and a NNT of 143 to prevent one ischemic event 
(0.7% absolute risk reduction) during 1 year of treatment. 
 
Validation in the PREFER Prolongation Study 
The identified clusters for thromboembolic and major bleeding events were 
independently validated in the PREFER Prolongation Study, which enrolled 
3156 AF patients receiving a NOAC for stroke prevention. Rivaroxaban was 
used in 50%, apixaban in 26% and dabigatran in 24% of patients. Clinical 
characteristics were similar to the derivation cohort in terms of age (72±9 
years), gender (40% female), stroke risk (CHA2DS2-VASc 3.3±1.6) and 
bleeding risk (HAS-BLED 1.9±1.1) (Table 1). 
Labile INR was reported in 6.9% of patients in the validation cohort, and 
validation was performed disregarding labile INR, as well as accounting for 
labile INR as a surrogate for poor compliance. 
The clusters of risk factors for thromboembolic events and major bleeding had 
numerically higher c-indices than established risk scores for the respective 
outcomes, consistent with results from the derivation cohort (Supplementary 
able 4). Lower absolute c-indices and non-significant differences regarding 
the predictive performance between the scores are reflected by a lower 
sample size and a lower incidence of outcome events in the validation cohort.  
Validation results were consistent when labile INR was accounted for as a 
surrogate for poor compliance (Supplementary Table 5). 
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 DISCUSSION 
The main finding of this study is that in a large cohort of anticoagulated AF 
patients, modifiable risk factors can be attributed to a substantial proportion of 
both thromboembolic and major bleeding events. In addition, this analysis 
confirmed other risk factors for embolic and bleeding events in anticoagulated 
AF patients such as prior stroke, older age, and heart failure. Major modifiable 
factors were labile INR values (in patients treated with vitamin K antagonists), 
concomitant therapy with antiplatelet agents or NSAIDs, and as a potentially 
modifiable risk factor liver damage. 
The modifiable risk factors identified here overlap with modifiable bleeding risk 
factors highlighted in the 2016 ESC atrial fibrillation guidelines (uncontrolled 
hypertension, labile INR, antiplatelet drugs or NSAIDs, and excess alcohol 
intake). 1 Our estimates suggest that patients in whom modifiable bleeding 
risk factors are minimised as part of an integrated management approach for 
AF might also be at lower risk for thromboembolic events. 9-17 Also in line with 
previous data, our analysis demonstrates that the CHA2DS2-VASc score was 
inferior in terms of bleeding risk prediction compared to the HAS-BLED score, 
and should not be used to estimate bleeding risk in anticoagulated AF 
patients. 19 20 27 
Simple measures that could be helpful to reduce residual thromboembolic and 
major bleeding events in anticoagulated patients suggested by our analysis 
include  
1. Switching from a Vitamin K antagonist to a NOAC in patients with 
labile INR values and 
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2. Timely discontinuation of antiplatelet therapy and minimisation of 
treatment with NSAIDs 
As shown previously, patients with well controlled INR values have a 
significantly lower risk for adverse cardiovascular outcomes. Adding time in 
therapeutic range to established bleeding risk stratification schemes such as 
the ATRIA and ORBIT score significantly improved their predictive 
performance. 28-30 This further underlines the importance of a high quality 
anticoagulation control in case VKA are used, and the need for adequate 
adherence to NOACs. 31 
Blood pressure was well controlled in our cohorts, thus limiting our ability to 
quantify the impact of uncontrolled hypertension on thromboembolic events 
and major bleeding. 1 32  
Successful treatment of chronic kidney or liver disease may contribute to 
improve outcomes. 1 33 Liver disease may also be a proxy for alcohol abuse, a 
factor that has been associated with bleeding in other cohorts. 34 
 
Our results also support the concept that the initiation or withdrawal of 
anticoagulation should not be based on bleeding risk, as stroke risk and 
bleeding risk are intricately linked. Instead, the increasing returns in terms of 
net clinical benefit - by treating subjects with greater thromboembolic risk - 
should be considered when initiating oral anticoagulation in AF patients. 4 35 36 
Importantly, we have been able to validate our findings in a cohort of AF 
patients anticoagulated with NOACs.  
 
LIMITATIONS AND STRENGHTS 
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The management of patients in included in the PREFER in AF registry is well 
aligned with evidence-based therapy and current treatment guidelines, 
underlining the generalisability of our findings in contemporary clinical 
practice. Worth mentioning, the derivation and validation cohort were recruited 
consecutively, thus in different periods in time (January 2012 - January 2013 
and June 2014 - May 2015). We cannot fully explain the association of the 
risk factors identified in this analysis with both major bleeding and 
thromboembolism. Importantly, our findings are based on associations and 
hence hypothesis-generating. While we were able to validate our findings in 
an independent cohort, interventional trials testing the simple interventions 
identified in our analysis are desirable to assess their effect on 
thromboembolic and major bleeding outcomes.  
While it seems intuitive that labile INR values predispose to both bleeding and 
stroke, it is less clear how concomitant therapy with antiplatelet agents or 
NSAIDs can contribute to stroke risk. It is conceivable that bleeding events led 
to temporary disruption of anticoagulation, thereby increasing the risk for 
thromboembolic events. In addition, concomitant therapy with these 
substances could be a marker for patients at higher risk of ischemic events 
due to confounders that were not captured in our data set. 
 
CONCLUSION 
A substantial number of thromboembolic and major bleeding events in 
anticoagulated patients with AF can be attributed to a few modifiable risk 
factors. For each single point decrease on an adjusted modifiable bleeding 
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risk scale, we observed an approximately 30% reduction in both major 
bleeding and thromboembolic events.  
Our findings suggest that normalising INR, avoiding exposure to antiplatelet 
agents or NSAIDs, and preventing liver disease could reduce both bleeding 
and residual stroke risk in AF patients receiving anticoagulation.  
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FIGURE LEGENDS 
 
Figure 1: Risk factors for thromboembolic events in anticoagulated atrial 
fibrillation patients, presented as odds ratios with 95% confidence intervals 
(PREFER in AF derivation cohort)  
* Concomitant therapy with antiplatelet agents or non-steroidal anti-
inflammatory drugs 
 
Figure 2: Risk factors for major bleeding events in anticoagulated atrial 
fibrillation patients, presented as odds ratios with 95% confidence intervals 
(PREFER in AF derivation cohort)  
* Concomitant therapy with antiplatelet agents or non-steroidal anti-
inflammatory drugs 
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TABLES 
 
Table 1: Clinical characteristics of the study population 
 PREFER in AF study 
(derivation cohort, 
only anticoagulated 
patients)  
N= 5310 
PREFER in AF 
Prolongation Study  
(validation cohort) 
N=3156 
Age 72.1 ± 9.8  72.1 ± 9.4 
Gender (female) 39.5% 40.3% 
BMI 28.1± 5.0  28.1± 4.9 
SBP (mean) 131.7± 16.5  134.2± 16.2 
DBP (mean) 77.6± 10.2     78.7± 10.0     
CHADS2 score (mean/median,Q1,Q3) 2.0 ± 1.3  
2 (1; 3) 
2.0 ± 1.2  
2 (1; 3) 
CHA2DS2-Vasc (mean/median,Q1,Q3) 3.5 ± 1.7  
3 (2; 5) 
3.3 ± 1.6  
3 (2; 4) 
CHA2DS2-VASc >= 2 88.0% 88.6% 
HAS-BLED score 
(mean/median,Q1,Q3) 
2.0 ± 1.1  
2 (1; 3) 
1.9 ± 1.1  
2 (1; 3) 
HAS-BLED >= 3 30.8% 26.1% 
   
Congestive heart failure  31.0% 22.1% 
Hypertension 73.1% 76.6% 
Diabetes  23.7% 22.9% 
Prior stroke/TIA  17.3% 15.7% 
Vascular disease 23.4% 14.9% 
Abnormal liver function  1.9% 0.9% 
Abnormal renal function 13.7% 18.5% 
Prior bleeding 4.8% 4.3% 
Labile INR unstable/high INRs, 
<60% time in therapeutic range 
15.3% 8.6% 
   25 
Drugs (antiplatelet agents, NSAID)  20.1% 14.0% 
Excess alcohol intake 2.5% 3.6% 
Legend: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic 
blood pressure; TIA: transient ischemic attack; INR: international normalised 
ratio; NSAID: non-steroidal anti-inflammatory drugs 
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Table 2: Incidence of thromboembolic events in the PREFER in AF study 
(derivation cohort) and the PREFER in AF Prolongation study (validation 
cohort) 
 Events 
(count) 
Annual Event Rates (95% 
Confidence Intervals) 
PREFER in AF (derivation 
cohort) 
  
Stroke or SEE 124 2.34% (1.93, 2.74) 
 - Ischemic stroke 43 0.81% (0.59, 1.09) 
 - TIA 64 1.21% (0.93, 1.54) 
 - Embolic Events* 27 0.51% (0.34, 0.74) 
PREFER in AF Prolongation 
(validation cohort) 
  
Stroke or SEE 53 1.68% (1.26, 2.19) 
 - Ischemic stroke 24 0.76% (0.49, 1.13) 
 - TIA 27 0.86% (0.56, 1.24) 
 - Embolic Events* 6 0.19% (0.07, 0.41) 
*Including arterial embolism, venous thromboembolism or pulmonary 
thromboembolism 
Legend: SEE: systemic embolic event; TIA: transient ischemic attack 
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Table 3: Risk factors associated with thromboembolic events (PREFER 
in AF derivation cohort) 
Variable OR 95% CI p-value 
Score 
Abnormal liver function * 2.86 1.24- 6.63 0.0141 2 
Labile INR ** 2.83 1.83- 4.38 <.0001 2 
Concomitant therapy with antiplatelet 
agents or non-steroidal anti-
inflammatory drugs 
2.41 1.58- 3.69 <.0001 1 
Prior stroke/TIA/thromboembolic event 2.79 1.81- 4.28 <.0001 2 
Heart failure 2.20 1.45- 3.33 0.0002 1 
Age ≥75 years 1.53 1.00- 2.33 0.0482 1 
 
Legend: OR: odds ration; CI: confidence interval; INR: international 
normalised ratio; TIA: transient ischemic attack;  
* Presence of cirrhosis, elevated liver transaminases or alkaline phosphatase 
>3 times above the upper limit of normal (ULN), or bilirubin >2 times above 
the ULN 
**  <60% time in therapeutic range 
*** antiplatelet agents or non-steroidal anti-inflammatory drugs 
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Table 4: Risk factors associated with major bleeding (PREFER in AF 
derivation cohort) 
Variable 
OR†  
 
95% CI 
p-
value 
OR§  
 
95% CI p-
value 
Score 
Bleeding predisposition* 4.10 2.54- 6.60 <0.0001 3.87 2.32- 6.47 <0.0001 4 
Age ≥ 75 years 2.16 1.52- 3.07 <0.0001 1.99 1.36- 2.91 0.0004 2 
Vascular disease** 1.92 1.35- 2.73 0.0003 1.65 1.11- 2.43 0.0125 1 
Abnormal renal function*** 1.78 1.18- 2.69 0.0062 1.50 1.01- 2.23 0.0401 1 
Abnormal liver function*** 3.48 1.65- 7.35 0.0011 3.24 1.47- 7.15 0.0035 2 
Labile INR**** 1.44 1.00- 2.08 0.0492 1.31 0.91- 1.89 0.0965 1 
Excess alcohol 1.85 1.07- 3.20 0.0134 1.94 1.02- 3.69 0.0472 2 
Drugs*****  1.78 1.23- 2.58 0.0023 1.35 0.89- 2.05 0.1581 1 
 
Legend: OR: odds ratio; CI: confidence interval; INR: international normalised 
ratio 
 
† Univariate analysis 
§ Multivariable Analysis 
* History of bleeding/anaemia (HAS-BLED) 
** Peripheral artery disease, prior myocardial infarction, aortic plaque 
(CHA2DS2-VASc) 
*** Abnormal renal function (HAS-BLED): serum creatinine >2.3 mg/dL (200 
μmol/L), renal transplantation or chronic dialysis. Abnormal liver function 
(HAS-BLED): cirrhosis, elevated liver transaminases or alkaline phosphatase 
>3 times above the upper limit of normal (ULN), or bilirubin >2 times above 
the ULN 
****  <60% time in therapeutic range 
***** Antiplatelet agents or non-steroidal anti-inflammatory drugs 
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